# Daily Iteration Report — 2026-08-02 (Sunday)

**Agent:** diabetes-research-iterate (autonomous scheduled run)
**Corpus state:** 286 papers — 273 VETTED / 13 FLAGGED / 0 UNVETTED (no vetting backlog)
**Weekly PubMed sweep:** skipped (not Monday)

## Work completed this run

### 1. Credibility sweep (Step 4 — every run) — CLEAN
Grepped all `Analysis/Scripts/*.py` for the three red-flag classes:
- **Fabricated PMIDs (≥42000000):** none found.
- **"zero SAEs" / "zero rejection":** none found.
- **"cure/curative/reverses diabetes" preclinical overstatement:** all hits are legitimate — dashboard category labels ("T1D Cure & Cell Therapy"), search-query strings, or appropriately hedged prose ("could cure," "theoretically cost-effective," "human data pending"). No fix required.

### 2. Path validation — `vitamin_d -> autoimmune` (stalest distinct partial)
Previous validation 2026-06-23. Re-checked against current literature.

**Rating: REMAINS PARTIALLY_VALIDATED.**

- **Interventional evidence still null:** 2025 systematic review/meta-analysis (Front Immunol, **PMID 40270966** / PMC12014702, 15 studies) — vitamin D supplementation does not significantly modify odds of incident T1D (pooled OR 0.55, 95% CI 0.22–1.38) or islet autoimmunity (OR 0.91, 95% CI 0.67–1.25). RR for T1D 0.66 (0.41–1.06), near but not significant.
- **New observational support (does not change rating):** JCEM, May 2026, **PMID 41162339** (Carry et al., DAISY cohort, n=143 high-genetic-risk children who developed islet autoimmunity). Higher vitamin D metabolite ratio (VMR) associated with protection against progression from islet autoimmunity to T1D. Biomarker/observational — strengthens the mechanistic/association side but not the interventional case.
- **Net:** observational + mechanistic association strengthened; supplementation (interventional) evidence remains non-significant. Rating held. External PMIDs updated in state. Next re-check ~2026-09-15.

### 3. Pipeline rebuild (Step 5)
Ran `run_quality_improvements.py`. All **24 offline dashboard/analysis builders completed [OK]** (clinical-trial dashboard, research dashboard, gap analyses, 15 gap deep-dives, equity maps, LADA/islet models, corpus analysis, research paths, statistical analysis, website, post-processing). Network PMID-verification scripts (`verify_pmids`, `ingest_papers`) ran slowly against the PubMed API in the sandbox, as in prior runs — offline research artifacts are complete and current.

## State & git
- `agent_state.json` updated (run recorded, queue reprioritized, `vitamin_d -> autoimmune` validation refreshed). Backup written.
- **Git push remains BLOCKED** (queue item #1): no GitHub auth in sandbox + OneDrive-protected `.git` lock files. All research changes persist to working files on disk regardless. User must commit/push from local PowerShell.

## Suggested next-run priorities
1. Re-validate next stalest distinct partial: `metformin -> cardiovascular` (2026-07-24) or `rapamycin -> inflammation` (2026-08-01).
2. Monthly gap audits due ~2026-08-16 (Gap #3 GOLD, Gap #6 GOLD).
3. PubMed re-indexing re-verify (2026-08-10): NLRP3→ferroptosis DKD (DOI 10.3390/ijms27104257) and Zhao hub-gene (iid3.70424) — both DOI-verified, still no PMID.
4. Monday 2026-08-03: weekly new-paper sweep.

*Research synthesis only — not medical advice. No PMIDs, citations, or data fabricated.*
